1. Worobey M, Gemmel M, Teuwen DE, et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature. 2008;455(7213):661-664.

2. Bailes E, Gao F, Bibollet-Ruche F, et al. Hybrid origin of SIV in chimpanzees. Science. 2003;300(5626):1713.

3. Centers for Disease Control and Prevention. HIV-2 infection surveillance—United States, 1987–2009. MMWR. 2011;60(29):985-988.

4. Urden LD, Stacy KM, Lough ME. Critical Care Nursing: Diagnosis and Management. 8th ed. Maryland Heights, MO: Elsevier; 2017.

5. UNAIDS. Fact Sheet 2022: Global HIV Statistics. Available at https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Last accessed February 27, 2023.

6. U.S. Department of State. U.S. Efforts to Combat the HIV/AIDS Pandemic in Africa: A Special Briefing by Randall Tobias, U.S. Global AIDS Coordinator [Archive]. Available at https://2001-2009.state.gov/s/gac/rl/rm/47810.htm. Last accessed February 27, 2023.

7. U.S. Department of State. About Us - PEPFAR. Available at https://www.state.gov/about-us-pepfar/. Last accessed February 27, 2023.

8. U.S. Congress. S. 1545 (113th): PEPFAR Stewardship and Oversight Act of 2013. Available at https://www.govtrack.us/congress/bills/113/s1545/text. Last accessed February 27, 2023.

9. HIV.gov. U.S. Statistics: Fast Facts. Available at https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics. Last accessed February 27, 2023.

10. Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas, 2020. Available at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html. Last accessed February 27, 2023.

11. Washington State Department of Health, Office of Infectious Disease Assessment Unit. Washington State HIV Surveillance Report: 2021 Edition. Available at https://doh.wa.gov/sites/default/files/2022-03/150-030-HIVSurveillanceReport2021.pdf. Last accessed February 27, 2023.

12. Simon V, Ho DD, Karim Q A. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368(9534):489-504.

13. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33-39.

14. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. The Guide to Clinical Preventive Services, 2014. Available at https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-providers/guidelines-recommendations/guide/cpsguide.pdf. Last accessed February 27, 2023.

15. U.S. Preventive Services Task Force. Human Immunodeficiency Virus (HIV) Infection: Screening. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening. Last accessed February 27, 2023.

16. Branson BM, Owen SM, Wesolowski LG, et al. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at https://stacks.cdc.gov/view/cdc/23447. Last accessed February 27, 2023.

17. National Center for HIV/AIDS, Viral Hepatitis, and TB Prevention (U.S.). Division of HIV/AIDS Prevention. 2018 Quick Reference Guide: Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens. Available at https://stacks.cdc.gov/view/cdc/50872. Last accessed February 27, 2023.

18. Revised Code of Washington. Chapter 70.24.330 RCW Dispositions. Control and Treatment of Sexually Transmitted Diseases. Section 70.24.330: HIV Testing-Consent, Exceptions. Available at https://apps.leg.wa.gov/rcw/dispo.aspx?cite=70.24.330. Last accessed February 21, 2023.

19. JUSTIA US Law. 2016 Revised Code of Washington Title 70 – Public Health and Safety 70.24 Control and Treatment of Sexually Transmitted Diseases. 70.24.330 HIV Testing – Consent, Exceptions. Available at https://law.justia.com/codes/washington/2016/title-70/chapter-70.24/section-70.24.330/. Last accessed February 27, 2023.

20. Hanssen I. An intercultural nursing perspective on autonomy. Nursing Ethics. 2004;11(1):28-41.

21. Carrese J, Rhodes L. Western bioethics on the Navaho reservation: benefit or harm? JAMA. 1995;274:826-829.

22. Rashad AM, MacVane Phipps F, Haith-Cooper M. Obtaining informed consent in an Egyptian research study. Nursing Ethics. 2004;11(4):394-399.

23. Yick A, Berthold SM. Conducting research on violence in Asian American communities: methodological issues. Violence Vict. 2005;20(6):661-677.

24. Washington State Legislature. Washington Administrative Code Chapter 246-100 Communicable and Certain Other Diseases. Available at https://apps.leg.wa.gov/wac/default.aspx?cite=246-100. Last accessed February 27, 2023.

25. King County. Summary of Washington State HIV/AIDS Reporting Requirements and Regulations. Available at https://www.kingcounty.gov/depts/health/communicable-diseases/hiv-std/patients/epidemiology/hiv-reporting-requirements.aspx. Last accessed February 27, 2023.

26. Branson BM, Handsfield HH, Lampe MA, et al. H. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR14):1-17.

27. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, National Minority AIDS Council, Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014: Summary for Clinical Providers. Rockville, MD: U.S. Department of Health and Human Services; 2014.

28. Centers for Disease Control and Prevention. HIV and Its Transmission FactSheet. Available at https://www.tdi.texas.gov/pubs/videoresource/fshiv.pdf. Last accessed February 27, 2023.

29. Jin F, Jansson J, Law M, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS. 2010;24(6):907-913.

30. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118-129.

31. Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;1:CD003255.

32. Giannou FK, Tsiara CG, Nikolopoulos GK, et al. Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):489-499.

33. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337-344.

34. Millett G, Malebranche D, Mason B, Spikes P. Focusing "down low:" bisexual black men, HIV risk and heterosexual transmission.J Natl Med Assoc. 2005;97(7 Suppl):52S-59S.

35. Centers for Disease Control and Prevention. Ways HIV Can be Transmitted. Oral Sex. Available at https://www.cdc.gov/hiv/basics/hiv-transmission/ways-people-get-hiv.html. Last accessed February 27, 2023.

36. Lab Tests Online. HIV Viral Load. Available at https://labtestsonline.org/tests/hiv-viral-load. Last accessed February 27, 2023.

37. Centers for Disease Control and Prevention. HIV transmission through transfusion—Missouri and Colorado, 2008. MMWR. 2010;59(41):1335-1339.

38. Leveton LB, Sox HC Jr, Stoto MA (eds). HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Washington, DC: National Academies Press; 1995.

39. Centers for Disease Control and Prevention. Healthcare-Associated Infections. Protecting Healthcare Personnel. Available at https://www.cdc.gov/hai/prevent/ppe.html. Last accessed February 27, 2023.

40. Levesque A, Bruneau J, Jutras-Aswad D, et al. Psychological distress increases needle sharing among cocaine users: results from the COSMO Study. J Addict Res Ther. 2014; S10:003.

41. Centers for Disease Control and Prevention. Summary of Information on The Safety and Effectiveness of Syringe Services Programs (SSPs). Available at https://www.cdc.gov/ssp/syringe-services-programs-summary.html#. Last accessed February 27, 2023.

42. Centers for Disease Control and Prevention. Syringe Disinfection for Injection Drug Users. The Academy for Educational Development, 2004.

43. Siberry GK. Preventing and managing HIV infection in infants, children, and adolescents in the United States. Pediatr Rev. 2014;35(7):268-286.

44. Flynn PM, Abrams EJ. Prevention of Mother-to-Child HIV Transmission in Resource-Limited Settings. Available at https://www.uptodate.com/contents/prevention-of-mother-to-child-hiv-transmission-in-resource-limited-settings. Last accessed February 27, 2023.

45. Centers for Disease Control and Prevention. HIV and Perinatal Transmission. Available at https://www.cdc.gov/hiv/group/pregnant-people/index.html. Last accessed February 27, 2023.

46. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at https://npin.cdc.gov/publication/recommendations-use-antiretroviral-drugs-pregnant-hiv-1-infected-women-maternal-health. Last accessed February 27, 2023.

47. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl. 2008;14(11):1603-1608.

48. Centers for Disease Control and Prevention. HIV transmitted from a living organ donor—New York City, 2009. MMWR. 2011;60(10):297-301.

49. Boyarsky BJ, Durand CM, Palella FJ Jr, Segev DL. Challenges and clinical decision-making in HIV-to-HIV transplantation: insights from the HIV literature. Am J Transplant. 2015;15(8):2023-2030.

50. Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation: results at 3 to 5 years. N Engl J Med. 2015;372(7):613-620.

51. Organ Procurement and Transplantation Network. HOPE Act. Available at https://optn.transplant.hrsa.gov/professionals/by-topic/hope-act/. Last accessed February 27, 2023.

52. U.S. National Library of Medicine. ClinicalTrials.gov. HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients. Available at https://clinicaltrials.gov/ct2/show/NCT03500315. Last accessed February 27, 2023.

53. Congress.Gov. H.R.6458 – National Organ Transplant Act Amendments of 2018. Available at https://www.congress.gov/bill/115th-congress/house-bill/6458. Last accessed February 27, 2023.

54. Centers for Disease Control and Prevention. Occupational HIV Transmission and Prevention Among Health Care Workers. Available at https://www.cdc.gov/hiv/pdf/workplace/cdc-hiv-healthcareworkers.pdf. Last accessed February 27, 2023.

55. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875-892.

56. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at https://clinicalinfo.hiv.gov/en/guidelines/perinatal/arv-counseling-guide. Last accessed February 27, 2023.

57. Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel. JAMA. 2023;329(1):63-84.

58. Dominguez KL, Smith DK, Thomas V, et al. Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV – United States, 2016. Available at https://stacks.cdc.gov/view/cdc/38856. Last accessed February 27, 2023.

59. Centers for Disease Control and Prevention. AIDS and Opportunistic Infections. Available at https://www.cdc.gov/hiv/basics/livingwithhiv/opportunisticinfections.html. Last accessed February 27, 2023.

60. Breuner CC, Mattson G, American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health. Sexuality education for children and adolescents. Pediatrics. 2016;138(2):e1-e11.

61. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Last accessed February 27, 2023.

62. HIVinfo.NIH.gov. FDA-Approved HIV Medicines. Available at https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines. Last accessed February 27, 2023.

63. Drugs.com. Pfizer's Selzentry (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA. Available at https://www.drugs.com/newdrugs/pfizer-s-selzentry-maraviroc-novel-hiv-approved-fda-595.html. Last accessed February 27, 2023.

64. Drugs.com. ViiV Healthcare Announces FDA Approval of Selzentry (maraviroc) for Use in Children and Adolescents Living with HIV. Available at https://www.drugs.com/newdrugs/viiv-healthcare-announces-fda-approval-selzentry-maraviroc-children-adolescents-living-hiv-4454.html. Last accessed February 27, 2023.

65. Aidsmap. Raltegravir Receives Accelerated Approval From the FDA. Available at https://www.aidsmap.com/news/oct-2007/raltegravir-receives-accelerated-approval-fda. Last accessed February 27, 2023.

66. U.S. Food and Drug Administration. FDA Approves New Drug to Treat HIV Infection [Archive]. Available at https://wayback.archive-it.org/7993/20170112023854/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm. Last accessed February 27, 2023.

67. Merck. News Releases. Merck Receives FDA Approval for ISENTRESS (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Newborns Weighing at Least 2 kg. Available at https://www.merck.com/news/merck-receives-fda-approval-for-isentress-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-newborns-weighing-at-least-2-kg/. last accessed February 27, 2023.

68. U.S. Food and Drug Administration. FDA Approves New HIV Treatment for Patients with Limited Treatment Options. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-limited-treatment-options. Last accessed February 27, 2023.

69. Larson KB, Wang K, Delille C, Otofokun I, Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet. 2014;53(10):865-872.

70. U.S. Food and Drug Administration. FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv. Last accessed February 27, 2023.

71. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.

72. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-822.

73. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf. Last accessed February 27, 2023.

74. Centers for Disease Control and Prevention TB and HIV Coinfection. Available at https://www.cdc.gov/tb/topic/basics/tbhivcoinfection.htm. Last accessed February 27, 2023.

75. Centers for Disease Control and Prevention, National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Recomm Rep. 2009;58(RR4):1-207.

76. U.S. Department of Health and Human Services, Health Resources and Services Administration. Guide for HIV/AIDS Clinical Care: 2014 Edition. Rockville, MD: U.S. Department of Health and Human Services, 2014.

77. UNAIDS Global HIV and AIDS Statistics – Fact Sheet. Available at https://www.unaids.org/en/resources/fact-sheet. Last accessed February 27, 2023.

78. Kaiser Family Foundation. Women and HIV/AIDS in the United States. Available at https://www.kff.org/hivaids/fact-sheet/women-and-hivaids-in-the-united-states/. Last accessed February 27, 2023.

79. Agency for Health Care Policy and Research. Many People with AIDS Change Their Minds About End-of-Life Care as the Disease Progresses. Available at http://archive.ahrq.gov/research/apr99/ra11.htm. Last accessed February 27, 2023.

80. Centers for Disease Control and Prevention. HIV and Women. Available at https://www.cdc.gov/hiv/group/gender/women/. Last accessed February 27, 2023.

81. Centers for Disease Control and Prevention. National Center for Health Statistics. Leading Causes of Death. Available at https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. Last accessed February 27, 2023.

82. Centers for Disease Control and Prevention. NCHHSTP AtlasPlus. Available at https://www.cdc.gov/nchhstp/atlas/index.htm. Last accessed February 27, 2023.

83. UNAIDS. HIV and AIDS – Basic Facts. Available at https://www.unaids.org/en/frequently-asked-questions-about-hiv-and-aids. Last accessed February 27, 2023.

84. Hewitt RG, Parsa N, Gugino L. The role of gender in HIV progression. BETA. 2001;14(1):13-16.

85. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol. 2008;168(5):532-540.

86. National Institutes of Health. Fiscal Years 2019-2020: Full Report on Research on Women's Health. Available at https://orwh.od.nih.gov/research/funded-research-and-programs/research-reports/biennial-report. Last accessed February 27, 2023.

87. MedlinePlus. HIV in Women. Available at https://medlineplus.gov/hivinwomen.html. Last accessed February 27, 2023.

88. American College of Obstetricians and Gynecologists. Practice bulletin no. 157: cervical cancer screening and prevention. Obstet Gynecol. 2016;127(1):e1-e20.

89. Maini MK, Gilson RJ, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med. 1996;72:27-31.

90. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19-26.

91. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis. 2015;15(2):181-189.

92. Haddad LB, Polis CB, Sheth AN, et al. Contraceptive methods and risk of HIV acquisition or female-to-male transmission. Curr HIV/AIDS Rep. 2015;11(4):447-458.

93. National Institute of Allergy and Infectious Diseases. Sex and Gender-Specific Health Challenges Facing Women: HIV/AIDS. Available at https://www.niaid.nih.gov/research/sex-specific-womens-health-challenges. Last accessed February 27, 2023.

94. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States, 2014. MMWR. 2014;63(RR3):1-10.

95. HIV.gov. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new#. Last accessed February 27, 2023.

96. Centers for Disease Control and Prevention. HIV in the United States by Age. Available at https://www.cdc.gov/hiv/group/age/index.html. Last accessed February 27, 2023.

97. Pilowsky DJ, Wu LT. Sexual risk behaviors and HIV risk among Americans aged 50 years or older: a review. Subst Abuse Rehabil. 2015;6:51-60.

98. U.S. Food and Drug Administration. Truvada for PrEP Fact Sheet: Ensuring Safe a Proper Use [Archive]. Available at https://wayback.archive-it.org/7993/20170406045104/https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM312290.pdf. Last accessed February 27, 2023.

99. U.S. Food and Drug Administration. FDA Approves Second Drug to Prevent HIV Infection as Part of Ongoing Efforts to End the HIV Epidemic. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic. Last accessed February 27, 2023.

100. U.S. Food and Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention. Last accessed February 27, 2023.

101. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.

102. Centers for Disease Control and Prevention. US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update: A Clinical Practice Guideline. Available at https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Last accessed February 27, 2023.

103. National Institute of Allergy and Infectious Diseases. HIV Vaccine Development. Available at https://www.niaid.nih.gov/diseases-conditions/hiv-vaccine-development. Last accessed February 27, 2023.

104. HIVinfo.gov. What is a Therapeutic HIV Vaccine? Available at https://hivinfo.nih.gov/understanding-hiv/fact-sheets/what-therapeutic-hiv-vaccine#. Last accessed February 27, 2023.

105. IAVI. Available at https://www.iavi.org/. Last accessed February 27, 2023.

106. International Partnership for Microbicides. What Are Microbicides? Available at https://www.ipmglobal.org/why-microbicides/arv-based-microbicides-and-how-they-work/what-are-microbicides. Last accessed February 27, 2023.

107. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174.

108. Underwood J, Brener N, Thornton J, et al. Youth Risk Behavior Surveillance—United States, 2019. MMWR. 2020;69(S1):1-83.

109. Breuner CC, Mattson G, American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health. Sexuality education for children and adolescents. Pediatrics. 2016;138(2):e1-e11.

110. Centers for Disease Control and Prevention. HIV/AIDS Prevention Research Synthesis Project. Available at https://www.cdc.gov/hiv/research/interventionresearch/prs/index.html. Last accessed February 27, 2023.

111. Washington State Legislature. Washington Administrative Code Chapter 246-101 Notifiable Conditions. Available at https://apps.leg.wa.gov/WAC/default.aspx?cite=246-101. Last accessed February 27, 2023.